JP2021501791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501791A5 JP2021501791A5 JP2020524894A JP2020524894A JP2021501791A5 JP 2021501791 A5 JP2021501791 A5 JP 2021501791A5 JP 2020524894 A JP2020524894 A JP 2020524894A JP 2020524894 A JP2020524894 A JP 2020524894A JP 2021501791 A5 JP2021501791 A5 JP 2021501791A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- pharmaceutical composition
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 206010043376 Tetanus Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 208000010772 Dog disease Diseases 0.000 claims description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000005647 Mumps Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 206010039509 Scab Diseases 0.000 claims description 2
- 208000037386 Typhoid Diseases 0.000 claims description 2
- 208000003152 Yellow Fever Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 201000005884 exanthem Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 201000008297 typhoid fever Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 17
- 206010026749 Mania Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 2
- -1 trehalose diesters Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NHAQNKDEUQPSIX-DXOCLGOBSA-N (2e,6s,7r,8e,11s)-6,7,15,17-tetrahydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),2,8,15,17-pentaen-13-one Chemical compound O=C1O[C@@H](C)C\C=C\[C@@H](O)[C@@H](O)CC\C=C\C2=CC(O)=CC(O)=C21 NHAQNKDEUQPSIX-DXOCLGOBSA-N 0.000 description 1
- NHAQNKDEUQPSIX-UHFFFAOYSA-N (3S,5E,7R,8S,11E)-7,8,14,16-tetrahydroxy-3-methyl-3,4,7,8,9,10-hexahydro-1H-benzo[c][1]oxacyclotetradecin-1-one Natural products O=C1OC(C)CC=CC(O)C(O)CCC=CC2=CC(O)=CC(O)=C21 NHAQNKDEUQPSIX-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- NHAQNKDEUQPSIX-CQDKDKBSSA-N aigialomycin D Natural products C[C@H]1CC=C[C@H](O)[C@@H](O)CCC=Cc2cc(O)cc(O)c2C(=O)O1 NHAQNKDEUQPSIX-CQDKDKBSSA-N 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- IDISMEQKBNKWJX-UHFFFAOYSA-N phenol;pyridine Chemical class C1=CC=NC=C1.OC1=CC=CC=C1 IDISMEQKBNKWJX-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ73694117 | 2017-11-02 | ||
| NZ736941 | 2017-11-02 | ||
| PCT/NZ2018/050156 WO2019088854A1 (en) | 2017-11-02 | 2018-11-02 | Brartemicin analogues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501791A JP2021501791A (ja) | 2021-01-21 |
| JP2021501791A5 true JP2021501791A5 (https=) | 2021-12-16 |
| JP7360385B2 JP7360385B2 (ja) | 2023-10-12 |
Family
ID=66332235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524894A Active JP7360385B2 (ja) | 2017-11-02 | 2018-11-02 | ブラルテミシン類似体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11510980B2 (https=) |
| EP (1) | EP3710462A4 (https=) |
| JP (1) | JP7360385B2 (https=) |
| AU (1) | AU2018361867B2 (https=) |
| WO (1) | WO2019088854A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018361867B2 (en) * | 2017-11-02 | 2023-08-10 | Victoria Link Ltd | Brartemicin analogues |
| CA3091352A1 (en) * | 2018-02-21 | 2019-08-29 | The University Of Montana | Diaryl trehalose compounds and uses thereof |
| JPWO2023277051A1 (https=) * | 2021-06-30 | 2023-01-05 | ||
| IL314325A (en) * | 2022-01-27 | 2024-09-01 | Citrachem Corp | Methods of synthesizing cannabidiol, derivatives thereof, and other phytocannabinoids |
| CN114796247B (zh) * | 2022-05-24 | 2023-08-08 | 广东医科大学 | 亚麻木酚素在制备抗轮状病毒药物的应用 |
| JPWO2024219501A1 (https=) * | 2023-04-20 | 2024-10-24 | ||
| JP7632857B1 (ja) | 2024-07-25 | 2025-02-19 | 博 村上 | 水溶性ｘ線造影剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307229A (en) * | 1979-11-07 | 1981-12-22 | Avraham Liav | 6,6'-Diesters of trehalose and process for the synthesis thereof |
| WO2010050178A1 (ja) | 2008-10-31 | 2010-05-06 | 大塚化学株式会社 | トレハロース化合物、その製造方法、及び該化合物を含有する医薬 |
| CN101914118B (zh) | 2010-08-06 | 2012-07-04 | 山东大学 | 海藻糖衍生物及其制备方法与应用 |
| CN102260297B (zh) * | 2011-06-07 | 2013-11-13 | 山东大学 | 海藻糖酰胺衍生物及其制备方法与应用 |
| AU2018361867B2 (en) * | 2017-11-02 | 2023-08-10 | Victoria Link Ltd | Brartemicin analogues |
| CA3091352A1 (en) * | 2018-02-21 | 2019-08-29 | The University Of Montana | Diaryl trehalose compounds and uses thereof |
-
2018
- 2018-11-02 AU AU2018361867A patent/AU2018361867B2/en active Active
- 2018-11-02 US US16/761,027 patent/US11510980B2/en active Active
- 2018-11-02 JP JP2020524894A patent/JP7360385B2/ja active Active
- 2018-11-02 EP EP18872712.7A patent/EP3710462A4/en active Pending
- 2018-11-02 WO PCT/NZ2018/050156 patent/WO2019088854A1/en not_active Ceased
-
2022
- 2022-10-19 US US18/047,708 patent/US20230139366A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501791A5 (https=) | ||
| JP7719769B2 (ja) | 抗ウイルスプロドラッグ及びその医薬組成物 | |
| JP3755890B2 (ja) | アジュバント含有ワクチン組成物 | |
| JP5759992B2 (ja) | 脂質付加オキソアデニン誘導体 | |
| Meyer et al. | Clinical investigations of Toll-like receptor agonists | |
| JP2021500394A5 (https=) | ||
| JPH0154324B2 (https=) | ||
| RU2015119999A (ru) | Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака | |
| JP2020531422A5 (https=) | ||
| JP2016515128A5 (https=) | ||
| JP2015535261A5 (https=) | ||
| JP6977206B2 (ja) | 自然免疫を活性化する粘膜ワクチン用アジュバント | |
| JP2017531038A5 (https=) | ||
| CA2632626A1 (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| JP2873313B2 (ja) | 化合物 | |
| JP2018512428A5 (https=) | ||
| JP2021502986A5 (https=) | ||
| CA2218701C (en) | Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof | |
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| JP2021502988A5 (https=) | ||
| JPWO2020006432A5 (https=) | ||
| CN1173705C (zh) | β－2－羟甲基－5－(5－氟胞嘧啶－1－基)－1,3－噁噻戊环在制药中的应用及含有该化合物的药物组合物 | |
| CA2555213C (en) | Nucleoside phosphonate derivatives useful in the treatment of hiv infections | |
| US20170304433A1 (en) | Vaccine compositions and methods of use to treat neonatal subjects | |
| CN111909204A (zh) | 一种替诺福韦双苯丙酸酯基氨基磷酸酯化合物及其药物组合物和用途 |